

Review Article

An Update on Risk Factors for Coronary Heart Disease and Dietary Recommendations for Treatment and Prevention

KR Padma¹, KR Don², B Dinesh³, D Karthikeyan⁴, M Vaishnavi⁵

¹Assistant Professor, Department of Biotechnology, Sri Padmavati Mahila Visvavidyalayam (Women's) University, Tirupati, Andhra Pradesh, India.

²Reader, Department of Oral Pathology and Microbiology, Sree Balaji Dental College and Hospital, Bharath Institute of Higher Education and Research (BIHER) Bharath University, Chennai, Tamil Nadu, India.

³Assistant Professor, Department of Dental Surgery, Government Stanley Medical College and Hospital, Chennai, India.

⁴Senior Assistant Professor, Maxillofacial Surgery, Department of Dental Surgery, Government Stanley Medical College, Chennai, India.

⁵Student, Department of Biotechnology, Sri Padmavati Mahila Visva Vidyalayam (Women's) University, Tirupati, Andhra Pradesh, India.

DOI: <https://doi.org/10.24321/2278.2044.202359>

I N F O

Corresponding Author:

KR Padma, Department of Biotechnology, Sri Padmavati Mahila Visvavidyalayam (Women's) University, Tirupati, Andhra Pradesh, India.

E-mail Id:

thulasipadi@gmail.com

Orcid Id:

<https://orcid.org/0000-0002-6783-3248>

How to cite this article:

Padma KR, Don KR, Dinesh B, Karthikeyan D, Vaishnavi M. An Update on Risk Factors for Coronary Heart Disease and Dietary Recommendations for Treatment and Prevention. Chettinad Health City Med J. 2023;12(3):105-114.

Date of Submission: 2023-01-26

Date of Acceptance: 2023-05-26

A B S T R A C T

Globally, cardiovascular disease (CVD) is the number one cause of death and disability. Knowing the CVD risk factors could provide crucial insights into how to handle this major public health issue and comprehend its genesis. Many clinical illnesses are linked to autonomic imbalance, which is defined by an overactive sympathetic and an underactive parasympathetic nervous system. Many hereditary and behavioural variables influence the likelihood of getting coronary heart disease (CHD). The CHD threat issues have an idiopathic origin, which suggests that the illness may pass down through generations as a result of genetic variance. Two further probable causes of CHD include autonomic dysfunction and the Omega-3 Index. Although dietary modification is a key component of CVD prevention, the implementation of nutrition science in clinical practice is constrained due to a dearth of formal education in the discipline. The precise elements of a heart-healthy diet, scientifically supported dietary recommendations, the effect of nutrition on the management and prevention of CVD risk factors are all subjects covered in this article. Its objective is to update the body of information on these emerging approaches (in vitro, translational, animal, clinical) and to explain the rationale behind their possible use in the treatment of CAD. These novel therapeutics have the potential to successfully replace current therapeutic modalities. Our report provides significant updates on the ongoing scientific and medical work being done around the world.

Keywords: Coronary Heart Disease, Idiopathic Cause, Autonomic Imbalance, Diet, Omega-3 Index, Therapy

Introduction

People worldwide are experiencing increasing disability and are dying from coronary heart disease (CHD).^{1,2} The world's biggest cause of death still is CHD.^{3,4} The key threat issues for CHD include total cholesterol-TC, Low-density lipoprotein (LDL-C), High-density lipoprotein (HDL-C), as well as hypertension, smoking, diabetes, blood sugar levels. Other elements that affect CHD risk include Estrogen Replacement Therapy (ERT), left ventricular hypertrophy, obesity, a family history of early CHD.⁵

Many variables might increase one's chance of getting CHD, some of which are influenced by both genetics and lifestyle choices.^{6,7} Many scientific investigations have discovered genetic polymorphisms substantially associated with CHD, they can account for 30%–60% of the difference in risk. Some techniques have been established for the pre-detection of genetic risk burden employing a variety of loci that can identify persons who are more at risk for incident CHD in big databases of epidemiological cohorts.^{8–15} A multilocus genetic risk score has not yet been definitively demonstrated to be independently associated with recurrent CHD events, however, a few specific individual variants have been investigated for an association with recurrent occurrences in isolated investigations.^{16–20}

This information in this study relates to the following:

- Risk factor prediction based on gender for coronary heart disease
- Diet and lifestyle that must be followed in order to prevent coronary heart disease
- Recent advancements in techniques in treating coronary heart disease

Epidemiology

CHD is the main reason for increasing death rates worldwide.^{21,22} The risk of getting CHD in women is 33% which is less when compared to men which is 50% as per a survey conducted for both men and women who were 40 years old.²³ Regarding the percentage of risk factors that lead to CHD, the contribution of risk factors varies between men and women. In recent decades, the death rate has decreased in places like North America and Western Europe.²⁴ There is a similar mortality rate among men and women, according to reports on mortality.²⁵ A study that included 997 women (15% of the study population) also revealed that death rate trends are more positive in women than in men. However, there is disagreement on mortality because a drop in mortality was seen following 5.2 years of significant research.²⁶ Study results, however, revealed that the first group of patients treated with lovastatin did not see a decrease in the incidence of hospitalisation as compared to those who suffered a myocardial infarction, suggesting a major breakthrough in medical care and a slight

decrease in the risk of cardiac arrest.²⁷ Furthermore, by lowering medicine avoidance in the first place, data from the World Health Organisation will allow for the profitable study of trends and causes in high-risk patients. When the MONICA project began, it was discovered that completely eliminating the incidence of this high-density cholesterol (HDL) allowed for a drop in the mortality rate of serious heart arrest.^{28–30}

It is necessary to conduct more research to identify the dietary modifications that are most practical from an economic, social, logistical standpoint. The public health priority of improving diet can significantly lower cardiovascular disease (CVD) morbidity and mortality at the population level. Clinicians must be aware of the most recent dietary recommendations in order to provide evidence-based nutritional counselling to patients who are at high risk for CVD. Therefore, modification and prevention of risk factors are helpful in order to stay away from CHD.

Omega-3 Index: An Up-to-date Peril Agent

Generally speaking, n-3 and n-6 are the two main types of polyunsaturated fatty acids (PUFAs). Double bonds are believed to start at location 6th from the CH-methyl end of omega 6, while the "Ω3 series" has double bonds that begin at position three. n-6 PUFAs are in charge of producing inflammatory mediators, whereas n-3 polyunsaturated fatty acids generate uncertain or anti-inflammatory signalling molecules. The phospholipids found in cell membranes contain arachidonic acid, a 6 PUFA that is crucial for the body's eicosanoids to be produced. PUFAs are a family, but depending on whether they come from plants or animals, they have different levels of potency. The three most significant and extensively studied PUFAs are Docosa Hexaenoic Acid (DHA), Eicosa Pentaenoic Acid (EPA), Alpha-Linolenic Acid (ALA).

Although a diet low in omega-3 FAs is linked to an elevated risk of mortality and CHD,^{31,32} assessing a person's Ω3 intake is not a good way to gauge how much Ω3 is present in their body because Ω3 concentrations vary among food categories, as well as among different kinds of fish and vegetables. Other factors that could affect the blood levels of omega-3 FAs after ingesting a meal high in omega-3 FAs include the heterogeneity of the uptake of ingested EPA and DHA as well as the variance in bioavailability across people (the levels of EPA and DHA in lean and pregnant women were compared to those in obese and pregnant women³³).

The risk of CHD death rate was inversely correlated with the Omega-3 Index. The greatest cardioprotection was shown to be related to an Omega-3 Index of 8%, while the least was found to be associated with an index of 4%.³⁴ The Omega-3 Index is an odd, functionally similar, easily variable, unusual tool that serves as the primary risk factor

for fatal CHD. However, research suggests that it may be highly conceptually beneficial in reducing CHD.³⁵ Three omega FAs decrease TG-rich lipoproteins and enhance anti-aggregatory and vasodilatory prostanoids like prostacyclin to avoid vasospasm and thrombosis. By integrating it into the mitochondria and plasma membranes, stabilising them, preventing oxidation, it is believed to contribute to the prevention of arrhythmias. Moreover, "3 omega FAs" have been demonstrated to suppress the activation of the nuclear factor-B and ikappa B kinase as well as a number of other transcription factors that inhibit reactive oxygen species, along with lower proinflammatory cytokines like interleukin-6 and tumour necrosis factor.^{36,37} They serve as building blocks for the creation of specific mediators that can lower inflammation.

Compared to direct anti-inflammatory treatments, anti-inflammatory qualities of omega-3 FAs were thought to lessen interference with self-protection. These pathways are thought to work in concert to provide the CVD protection linked to omega-3 FA consumption as well as the additional benefit on numerous other systems and diseases.³⁸ Table 1 shows the various agents that are an obstacle in the path of a healthy life.

Table 1. Men and Women's Peril Agents

Peril Agents	Men	Women
Low-density lipoprotein (LDL)	√√√	√√√
Total cholesterol levels (TC)	√√√√√	√√√√
High-density lipoprotein (HDL)	√√	√√√
Thyroglobulin (TG)	√	√√
Apolipoprotein AI (Apo A-I)	√√√√	√√√√
Apolipoprotein B (Apo-B)	√√√√	√√√√
Apolipoprotein (a) Apo (a)	√√	√√
Diabetes	√√√	√√√√
Smoking	√√√	√√√
Obesity	-	-
Body mass index (BMI)	√√√	√√√
Waist hip ratio (WHR)	√√√√	√√√√
Hypertension	√√	√√
Hormones	-	√√
Family history/ idiopathic cause	√√	√√√
Homocysteine	√	√
Fibrinogen	√√	√√
Inflammation	√	√√
Psychological factors	√	√
<i>Helicobacter pylori</i> infection and <i>Chlamydia pneumoniae</i>	-	-

Single tick (√): Low, Double tick (√√): Moderate, Triple tick (√√√): High, Four ticks (√√√√): Highest/ greatest

Perfect Diet for a Healthy Life

The manifestation of diseases caused by environmental factors is fortunately mostly avoidable because these factors are controllable. One of the main factors currently connected to a variety of ailments, including diabetes, is diet. A key factor affecting human health is the type and quantity of food ingested. Diet, which can be either diet-only, diet-plus-oral hypoglycaemic medicines or diet-plus-insulin, is a crucial part of managing diabetes holistically.³⁹⁻⁴¹ Diets are tailored to each individual based on factors such as weight, age, gender, health, occupation, etc.

Both healthy nutrition and health require a balanced diet. It protects us from many chronic, non-communicable diseases, like diabetes, cancer, heart disease.^{42,43} A balanced diet that excludes excessive amounts of salt, sugar, saturated fat, trans fats is necessary for good health.⁴⁴⁻⁴⁶

The dietary guidelines that were employed in this review are a group of advisory statements that offer rapid dietary advice for the population's treatment of cardiovascular issues in an effort to enhance general nutritional well-being and cholesterol control and avoid or lower LDL levels.

Dietary Recommendations for the Management of Cardiovascular Disease

A significant part in managing heart failure can be played by certain foods because they lower blood cholesterol levels. Consuming meals that shield against the consequences of heart and renal disease is also very important.⁴⁷

The chief diet foods that can significantly contribute to controlling the condition are as follows:

Leafy Vegetables



Figure 1. Green Leafy Vegetables

While being very nutrient-dense, green, leafy vegetables (Figure 1) are low in calories. They have a significant impact on metabolic regulation as well because they are low in digestible carbohydrates.⁴⁸

The dietary information for 100 g of leafy greens is as follows:⁴⁹

Water - 91%
Calories - 23 kcal

Protein - 2.9 g
Fibre - 2.2 g
Sugar - 0.4 g
Carbohydrates - 3.6 g
Fat - 0.4 g

Cinnamon



Figure 2.Cinnamon

Cinnamon (Figure 2) has a reputation for being a powerful antioxidant as well as a diabetes-controlling agent. Several carefully conducted studies have shown that cinnamon can lower blood lipid levels and enhance immune response. Cassia cinnamon should, however, only be consumed in amounts no greater than a teaspoon per day because this type of cinnamon contains coumarin, higher doses of which may have negative health effects. Ceylon cinnamon, on the other hand, does not have a lot of coumarins.

100 g of cinnamon has the following nutritional value:⁴⁹

Sodium - 10 mg
Fibre - 1.2 g
Sugar - 2.2 g
Carbohydrates - 81 g
Protein - 4 g
Potassium - 431 mg
Calories - 247 kcal

Fatty Fish



Figure 3.Fish

Salmon, sardines, mackerel can all be eaten by the populace suffering from CVD. These oily fish (Figure 3) are excellent providers of omega-3 fatty acids, DHA (docosahexaenoic acid) and EPA (Eicosapentaenoic acid), which have significant heart health advantages. Increasing these fats in the diet may be especially beneficial for diabetics, who have a higher risk of heart disease.

100 g of fatty fish has the following nutritional value:⁴⁹

Fat - 12.5 g
Calories - 280 kcal
Carbohydrates - 0 g
Sugar - 0 g
Sodium - 86 mg
Fibre - 0 g
Protein - 39.2 g

Chia Seeds



Figure 4.Chia Seeds

Chia seeds (Figure 4) have a high fibre content but have fewer easily absorbed carbohydrates. The viscous fibre present in these seeds reduces blood lipid levels. It accomplishes this by reducing the speed at which food passes through the intestines and is digested.

The nutritional information of 100 g of chia seeds is as follows:

Fat - 8.7 g
Carbohydrates - 12 g
Fibre - 9.8 g
Protein - 4.7 g
Sugar - 0 g
Calories - 138 kcal
Sodium - 5 mg

Greek Yoghurt



Figure 5.Greek Yoghurt

Greek yoghurt (Figure 5) can help in cardiovascular maintenance through a healthy reduction in blood cholesterol and triglyceride levels, which in turn, lowers their chance of developing heart disease.

155 g of Greek yoghurt has the following nutritional constituents:

Vitamin B₁₂ - 1.2 mcg
 Potassium - 220 mg
 Protein - 16.1 g
 Carbohydrates - 5.68 g
 Sodium - 56.2 mg
 Fat - 0.265 g
 Calories - 92 kcal
 Sugar - 5.1 g
 Calcium - 111 mg
 Vitamin B₆ - 0.1 mg

Flaxseeds

Insoluble fibre made up of lignans is present in flaxseeds (Figure 6), also referred to as alsin in India. It improves blood sugar management and lowers the risk of heart disease.



Figure 6. Flaxseeds

The dietary information for 1 tablespoon (10 g) of flaxseeds is as follows:

Fat - 4.3 g
 Carbohydrates - 3 g
 Calories - 55 kcal
 Protein - 1.9 g
 Sugar - 0.2 g
 Fibre - 2.8 g
 Sodium - 3.1 mg

Nuts



Figure 7. Nuts

It is well known that all nuts (Figure 7) contain fibre, although quantities vary, they are low in digestible fibre. Consuming nuts of all varieties can lower HbA1c and lessen inflammation, according to research. Additionally, it can reduce LDL cholesterol and blood sugar levels.

The nutrition information for 100 g of nuts is:

Carbohydrate - 21 g
 Fat - 54 g
 Protein - 20 g
 Saturated fat - 9 g
 Sodium - 273 mg
 Potassium - 632 mg
 Dietary fibre - 7 g
 Sugar - 4.2 g
 Calories - 607 kcal

For those with CVD issues, a low-fat vegetarian diet that includes portions of fruits, vegetables, grains, legumes, but no animal products, has benefits. A study showed that 43% of the vegan group experienced significant improvement in cardiovascular problems.⁴⁷ The American Diabetes Association's (ADA) advice is the foundation of the vegan diet. Among those who continued on their lipid-lowering medication regimens, the vegan group also had higher reductions in total and LDL cholesterol.^{50,51} Figure 8 shows the association of diet with CVD.




Figure 8. Prevention of Cardiovascular Disease through a Nutritional Diet

Recent Advancements in Treating Coronary Heart Disease

Over the past ten years, the application of robotic technology in cardiovascular medicine has grown to include interventional cardiology, percutaneous coronary procedures, peripheral vascular interventions. Research and technology are advancing day by day.⁵² Over the years, many advanced instruments and techniques have been developed for diagnosing several diseases. Along with this, scientists have developed several novel techniques like the use of artificial intelligence for detecting the threat of CHD.

Robotics

Over the past few years, robots have been used rapidly in industries.⁵³ Their use in the medical field started during the time when we were hit by the pandemic i.e., novel coronavirus. Robots are self-learning because their designs allow them to automatically respond correctly in certain situations. Medical students are taught a variety of therapies and surgical procedures with the use of robotic technology. They can practice various procedures on robots without having to worry about accidentally hurting a real patient. Robotic machines can mimic breathing, dilation of the pupils, birthing, beating of the heart. These tools are used by students to practice taking vital signs, inserting IVs, giving birth.

The current state of robotic surgery for the treatment of CHD is encouraging. These devices have top-notch technology and are of exceptional quality. Enhanced patient recovery times and shorter hospital stays are a few of their various advantages, which also include improved precision, increased visibility, improved ergonomics, lower radiation exposure (Figure 9).




Figure 9. Potential Advantages of Robotics in the Treatment of CHD

Several sectors related to life sciences have come up and are developing many advanced strategies for the early detection of the risk of CHD. They include nanobiotechnology, 3D printing, drugs, stem cells.⁵⁴⁻⁵⁹

Conclusion

This article provides updated information on the risk factors for coronary heart disease, new developments in this area, the recommended diet for the disease. Maintaining a balanced diet and getting enough nutrients and minerals we need each day keeps us in good health. Early detection of

CHD makes it much easier to take the essential precautions to prevent its progress. It is crucial to provide CVD patients with continuing, active, effective dietary guidance in order to prevent the development of the complications of CVD. Also, individuals must be provided with the resources necessary to control their weight, make better dietary choices, develop healthy eating routines. With the advancement and development of robotic technologies, a new era in interventional cardiology has also begun. Robotically assisted percutaneous coronary intervention (PCI) is a safe method with outcomes commensurate to those obtained by a manual method. Though it should always be remembered that “prevention is better than treatment”, with consistent, ongoing research, the future of CAD therapy seems to be highly hopeful.

Acknowledgement

All the authors are thankful to the Department of Biotechnology, Sri Padmavati Mahila Visvavidyalayam (Women’s) University, Tirupati, India, the Department of Oral Pathology and Microbiology, Sri Balaji Dental College and Hospital, Bharath Institute of Higher Education and Research (BIHER) Bharath University, Chennai, Tamil Nadu.

Source of Funding: None

Conflict of Interest: None

References

1. Bartel T, Rivard A, Jimenez A, Mestres CA, Muller S. Medical three-dimensional printing opens up new opportunities in cardiology and cardiac surgery. *Eur Heart J.* 2017;39(15):1246-54. [PubMed] [Google Scholar]
2. Dixit P, Katare R. Challenges in identifying the best source of stem cells for cardiac regeneration therapy. *Stem Cell Res Ther.* 2015;6(1):26. [PubMed] [Google Scholar]
3. Marco A, Marco P. Improvement in the cardiovascular profile of patients with morbid obesity following bariatric surgery: effect on hypercoagulability. *Medicine (Baltimore).* 2021;100(12):e25280. [PubMed] [Google Scholar]
4. Albert CM, Campos H, Stampfer MJ, Ridker PM, Manson JE, Willett WC, Ma J. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. *N Engl J Med.* 2002;346(15):1113-8. [PubMed] [Google Scholar]
5. Aggarwal A, Srivastava S, Velmurugan M. Newer perspectives of coronary artery disease in young. *World J Cardiol.* 2016;8(12):728-34. [PubMed] [Google Scholar]
6. Pan M, Pan X, Zhou J, Wang J, Qi Q, Wang L. Update on hormone therapy for the management of postmenopausal women. *Biosci Trends.* 2022;16(1):46-57. [PubMed] [Google Scholar]

7. Bonatti J, Vetrovec G, Riga C, Wazni O, Stadler P. Robotic technology in cardiovascular medicine. *Nat Rev Cardiol.* 2014;11(5):266-75. [PubMed] [Google Scholar]
8. Hamer M, Mishra GD. Dietary patterns and cardiovascular risk markers in the UK Low Income Diet and Nutrition Survey. *Nutr Metab Cardiovasc Dis.* 2010;20(7):491-7. [PubMed] [Google Scholar]
9. Huijbregts PP, Feskens EJ, Kromhout D. Dietary patterns and cardiovascular risk factors in elderly men: the Zutphen Elderly Study. *Int J Epidemiol.* 1995;24(2):313-20. [PubMed] [Google Scholar]
10. Lemaitre RN, King IB, Mozaffarian D, Kuller LH, Tracy RP, Siscovick DS. n-3 polyunsaturated fatty acids, fatal ischemic heart disease and nonfatal myocardial infarction in older adults: the Cardiovascular Health study. *Am J Clin Nutr.* 2002;77(2):319-25. [PubMed] [Google Scholar]
11. Gobbo LC, Imamura F, Aslibekyan S, Marklund M, Virtanen JK, Wennberg M, Yakoob MY, Chiuvè SE, Cruz LD, Frazier-Wood AC, Fretts AM, Guallar E, Matsumoto C, Prem K, Tanaka T, Wu JH, Zhou X, Helmer C, Ingelsson E, Yuan JM, Barberger-Gateau P, Campos H, Chaves PH, Djoussé L, Giles GG, Gómez-Aracena J, Hodge AM, Hu FB, Jansson JH, Johansson I, Khaw KT, Koh WP, Lemaitre RN, Lind L, Luben RN, Rimm EB, Risérus U, Samieri C, Franks PW, Siscovick DS, Stampfer M, Steffen LM, Steffen BT, Tsai MY, van Dam RM, Voutilainen S, Willett WC, Woodward M, Mozaffarian D; Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Fatty Acids and Outcomes Research Consortium (FORCe). ω -3 polyunsaturated fatty acid biomarkers and coronary heart disease: pooling project of 19 cohort studies. *JAMA Intern Med.* 2016;176(8):1155-66. [PubMed] [Google Scholar]
12. van Lennep JE, Westerveld HT, Erkelens DW, van der Wall EE. Risk factors for coronary heart disease: implications of gender. *Cardiovasc Res.* 2002;53(3):538-49. [PubMed] [Google Scholar]
13. Huang J, Huang S, Li J, Li M, Gong L, Li T, Gu L. CALM1 rs3179089 polymorphism might contribute to coronary artery disease susceptibility in Chinese male: a case-control study. *Genes Genomics.* 2021;44(4):415-23. [PubMed] [Google Scholar]
14. Javan R, Herrin D, Tangestanipoor A. Understanding spatially complex segmental and branch anatomy using 3D printing: liver, lung, prostate, coronary arteries, circle of Willis. *Acad Radiol.* 2016;23(9):1183-9. [PubMed] [Google Scholar]
15. Kris-Etherton PM, Harris WS, Appel LJ; American Heart Association. Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, cardiovascular disease. *Circulation.* 2002;106(21):2747-57. [PubMed] [Google Scholar]
16. Wojszel ZB, Kuźma L, Rogalska E, Kurasz A, Dobrzycki S, Sobkowicz B, Tomaszuk-Kazberuk A. A newly defined CHA₂DS₂-VA score for predicting obstructive coronary artery disease in patients with atrial fibrillation—a cross-sectional study of older persons referred for elective coronary angiography. *J Clin Med.* 2002;11(12):3462. [PubMed] [Google Scholar]
17. Zheng ZJ, Croft JB, Giles WH, Mensah GA. Sudden cardiac death in the United States, 1989 to 1998. *Circulation.* 2001;104(18):2158-63. [PubMed] [Google Scholar]
18. Luostarinen R, Boberg M, Saldeen T. Fatty acid composition in total phospholipids of human coronary arteries in sudden cardiac death. *Atherosclerosis.* 1993;99(2):187-93. [PubMed] [Google Scholar]
19. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Arson HR, Arson LM, Arsenau KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, Abdulhak AB, Birbeck G, Blyth F, Bolliger I, Boufous S, Bucello C, Burch M, Burney P, Carapetis J, Chen H, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, de Vaccaro KC, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahodwala N, De Leo D, Degenhardt L, Delossantos A, Denenberg J, Des Jarlais DC, Dharmaratne SD, Dorsey ER, Driscoll T, Duber H, Ebel B, Erwin PJ, Espindola P, Ezzati M, Feigin V, Flaxman AD, Forouzanfar MH, Fowkes FG, Franklin R, Fransen M, Freeman MK, Gabriel SE, Gakidou E, Gaspari F, Gillum RF, Gonzalez-Medina D, Halasa YA, Haring D, Harrison JE, Havmoeller R, Hay RJ, Hoen B, Hotez PJ, Hoy D, Jacobsen KH, James SL, Jasrasaria R, Jayaraman S, Johns N, Karthikeyan G, Kassebaum N, Keren A, Khoo JP, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lipnick M, Lipshultz SE, Ohno SL, Mabweijano J, MacIntyre MF, Mallinger L, March L, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGrath J, Mensah GA, Merriman TR, Michaud C, Miller M, Miller TR, Mock C, Mocumbi AO, Mokdad AA, Moran A, Mulholland K, Nair MN, Naldi L, Narayan KM, Nasseri K, Norman P, O'Donnell M, Omer SB, Ortblad K, Osborne R, Ozgediz D, Pahari B, Pandian JD, Rivero AP, Padilla RP, Perez-Ruiz F, Perico N, Phillips D, Pierce K, Pope 3rd CA, Porrini E, Pourmalek F, Raju M, Ranganathan D, Rehm JT, Rein DB, Remuzzi G, Rivara FP, Roberts T, De León FR, Rosenfeld LC, Rushton L, Sacco RL, Salomon JA, Sampson U, Sanman E, Schwebel DC, Segui-Gomez M, Shepard DS, Singh D, Singleton J, Sliwa K, Smith E, Steer A, Taylor JA, Thomas B, Tleyjeh IM, Towbin JA,

- Truelsen T, Undurraga EA, Venketasubramanian N, Vijayakumar L, Vos T, Wagner GR, Wang M, Wang W, Watt K, Weinstock MA, Weintraub R, Wilkinson JD, Woolf AD, Wulf S, Yeh PH, Yip P, Zabetian A, Zheng ZJ, Lopez AD, Murray CJ, AlMazroa MA, Memish ZA. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet*. 2012;380(9859):2095-128. [PubMed] [Google Scholar]
20. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, de Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, Stafford R, Thom T, Wasserthiel-Smoller S, Wong ND, Wylie-Rosett J; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics - 2010 update: a report from the American Heart Association. *Circulation*. 2010;121(7):948-54. [PubMed]
21. Malakar AK, Choudhury D, Halder B, Paul P, Uddin A, Chakraborty S. A review on coronary artery disease, its risk factors, therapeutics. *J Cell Physiol*. 2019;234(10):16812-23. [PubMed] [Google Scholar]
22. Ozuynuk AS, Erkan AF, Dogan N, Ekici B, Erginel-Unaltuna N, Kurmus O, Coban N. Examining the effects of the CLU and APOE polymorphisms' combination on coronary artery disease complexed with type 2 diabetes mellitus. *J Diabetes Complications*. 2022;36(1):108078. [PubMed] [Google Scholar]
23. Centers for Disease Control and Prevention [Internet]. About underlying cause of death 1999–2020; 2020 [cited 2023 Apr 28]. Available from: <http://wonder.cdc.gov/ucd-icd10.html>
24. Ko EJ, Kim IJ, Lee JY, Park HW, Park HS, Kim SH, Moon JY, Sung JH, Kim NK. Study of the Association between VEGF polymorphisms and the risk of coronary artery disease in Koreans. *J Pers Med*. 2022;12(5):761. [PubMed] [Google Scholar]
25. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Das SR, Delling FN, Djousse L, Elkind MS, Ferguson JF, Fornage M, Jordan LC, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, O'Flaherty M, Pandey A, Perak AM, Rosamond WD, Roth GA, Sampson UK, Satou GM, Schroeder EB, Shah SH, Spartano NL, Stokes A, Tirschwell DL, Tsao CW, Turakhia MP, VanWagner LB, Wilkins JT, Wong SS, Virani SS; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2019 update: a report from the American Heart Association. *Circulation*. 2019;139(10):e56-528. [PubMed] [Google Scholar]
26. Leite CF, Almeida TR, Lopes CS, Dias da Silva VJ. Multipotent stem cells of the heart-do they have therapeutic promise? *Front Physiol*. 2015;6:123. [PubMed] [Google Scholar]
27. Zhou MX, Tian X, Wu ZQ, Li K, Li ZJ. Fuzhuan brick tea supplemented with areca nuts: effects on serum and gut microbiota in mice. *J Food Biochem*. 2021;45(5):e13737. [PubMed] [Google Scholar]
28. Morbidity and mortality: 1996 chartbook on cardiovascular, lung, coronary events with lovastatin in men and women with average and blood diseases. Bethesda, MD, National Institutes of Health; 1996.
29. Marchioli R, Barzi F, Bomba E, Chieffo C, Gregorio DD, Mascio RD, Franzosi MG, Geraci E, Levantesi G, Muggioni AP, Mantini L, Marfisi RM, Mastrogioseppe G, Mininni N, Nicolosi GL, Santini M, Schweiger C, Tavazzi L, Tognoni G, Tucci C, Valagussa F; GISSI-Prevenzione Investigators. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. *Circulation*. 2002;105(16):1897-903. [PubMed] [Google Scholar]
30. Tunstall-Pedoe H, Kuulasmaa K, Mahonen M, Tolonel H, Ruokokoski E, Amouyel P. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. *Lancet*. 1999;353(9164):1547-57. [PubMed] [Google Scholar]
31. McNaughton SA, Mishra GD, Brunner EJ. Food patterns associated with blood lipids are predictive of coronary heart disease: the Whitehall II study. *Br J Nutr*. 2009;102(4):619-24. [PubMed] [Google Scholar]
32. Nettleton JA, Polak JF, Tracy R, Burke GL, Jacobs Jr DR. Dietary patterns and incident cardiovascular disease in the Multi-Ethnic Study of Atherosclerosis. *Am J Clin Nutr*. 2009;90(3):647-54. [PubMed] [Google Scholar]
33. Bernard JY, Pan H, Aris IM, Moreno-Betancur M, Soh SE, Yap F, Tan KH, Shek LP, Chong YS, Gluckman PD, Calder PC, Godfrey KM, Chong M, Kramer MS, Karnani N, Lee YS. Long-chain polyunsaturated fatty acids, gestation duration, birth size: a Mendelian randomization study using fatty acid desaturase variants. *Am J Clin Nutr*. 2018;108(1):92-100. [PubMed] [Google Scholar]
34. Hu Y, Hu FB, Manson JE. Marine omega-3 supplementation and cardiovascular disease: an updated meta-analysis of 13 randomized controlled

- trials involving 127,477 participants. *J Am Heart Assoc.* 2019;8(19):e013543. [PubMed] [Google Scholar]
35. Bernasconi AA, Lavie CJ, Milani RV, Laukkanen JA. Omega-3 benefits remain strong post-STRENGTH. *Mayo Clin Proc.* 2021;96(5):1371-2. [PubMed] [Google Scholar]
 36. Erkkila AT, Lehto S, Pyorala K, Uusitupa MI. n-3 fatty acids and 5-y risks of death and cardiovascular disease events in patients with coronary artery disease. *Am J Clin Nutr.* 2003;78(1):65-71. [PubMed] [Google Scholar]
 37. Park Y, Harris WS. Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance. *J Lipid Res.* 2003;44(3):455-63. [PubMed] [Google Scholar]
 38. Kurup HK, Samuel BP, Vettukattil JJ. Hybrid 3D printing: a game-changer in personalized cardiac medicine? *Expert Rev Cardiovasc Ther.* 2015;13(12):1281-4. [PubMed] [Google Scholar]
 39. De Caterina R, Massaro M. Omega-3 fatty acids and the regulation of expression of endothelial pro-atherogenic and pro-inflammatory genes. *J Membr Biol.* 2005;206(2):103-16. [PubMed] [Google Scholar]
 40. Welty FK, Alfaddagh A, Elajami TK. Targeting inflammation in metabolic syndrome. *Transl Res.* 2016;167(1):257-80. [PubMed] [Google Scholar]
 41. Mason RP, Libby P, Bhatt DL. Emerging mechanisms of cardiovascular protection for the omega-3 fatty acid eicosapentaenoic acid. *Arterioscler Thromb Vasc Biol.* 2020;40(5):1135-47. [PubMed] [Google Scholar]
 42. Sofi F, Innocenti G, Dini C, Masi L, Battistini NC, Brandi ML, Rotella CM, Gensini GF, Abbate R, Surrenti C, Casini A. Low adherence of a clinically healthy Italian population to nutritional recommendations for primary prevention of chronic diseases. *Nutr Metab Cardiovasc Dis.* 2006;16(6):436-44. [PubMed] [Google Scholar]
 43. Kastorini CM, Panagiotakos DB. Mediterranean diet and diabetes prevention: myth or fact? *World J Diabetes.* 2010;1(3):65-7. [PubMed] [Google Scholar]
 44. Feskens EJ, van Dam RM. Dietary fat and the etiology of type 2 diabetes: an epidemiological perspective. *Nutr Metab Cardiovasc Dis.* 1999;9(2):87-95. [PubMed] [Google Scholar]
 45. von Schacky C, Fischer S, Weber PC. Long-term effects of dietary marine omega-3 fatty acids upon plasma and cellular lipids, platelet function, eicosanoid formation in humans. *J Clin Invest.* 1985;76(4):1626-31. [PubMed] [Google Scholar]
 46. van Dam RM, Grievink L, Ocke MC, Feskens EJ. Patterns of food consumption and risk factors for cardiovascular disease in the general Dutch population. *Am J Clin Nutr.* 2003;77(5):1156-63. [PubMed] [Google Scholar]
 47. Valente HB, dos Santos Silva VE, Barros TR, Vanderlei FM, Laurino MJ, Botta AF, Vanzella LM, Bongiovani AC, Vanderlei LC. Relationship between the number of comorbidities, quality of life, cardiac autonomic modulation in patients with coronary disease: a cross-sectional study. *Rev Assoc Med Bras (1992).* 2022;68(4):450-5. [PubMed] [Google Scholar]
 48. Heidemann C, Schulze MB, Franco OH, van Dam RM, Mantzoros CS, Hu FB. Dietary patterns and risk of mortality from cardiovascular disease, cancer, all causes in a prospective cohort of women. *Circulation.* 2008;118(3):230-7. [PubMed] [Google Scholar]
 49. National Institute of Nutrition, Indian Council of Medical Research [Internet]. Dietary Guidelines for Indians – a manual; 2011 [cited 2023 Apr 18]. Available from: <https://www.nin.res.in/downloads/DietaryGuidelinesforNINwebsite.pdf> [Google Scholar]
 50. Hoffman K, Zyriax BC, Boeing H, Windler E. A dietary pattern derived to explain biomarker variation is strongly associated with the risk of coronary artery disease. *Am J Clin Nutr.* 2004;80(3):633-40. [PubMed] [Google Scholar]
 51. Kerver JM, Yang EJ, Bianchi L, Song WO. Dietary patterns associated with risk factors for cardiovascular disease in healthy US adults. *Am J Clin Nutr.* 2003;78(6):1103-10. [PubMed] [Google Scholar]
 52. Liese AD, Nichols M, Hodo D, Mellen PB, Schulz M, Goff DC, D'Agostino RB. Food intake patterns associated with carotid artery atherosclerosis in the Insulin Resistance Atherosclerosis Study. *Br J Nutr.* 2010;103(10):1471-9. [PubMed] [Google Scholar]
 53. Cheng L, Rong J, Zhuo X, Gao K, Meng Z, Wen X, Li S, Fan P, Hao X, Jian Z, Wu Y, Li B. Prognostic value of malnutrition using geriatric nutritional risk index in patients with coronary chronic total occlusion after percutaneous coronary intervention. *Clin Nutr.* 2021;40(6):4171-9. [PubMed] [Google Scholar]
 54. Centritto F, Iacoviello L, di Giuseppe R, de Curtis A, Costanzo S, Zito F, Grioni S, Sieri S, Donati MB, de Gaetano G, Di Castelnuovo A; Moli-sani Investigators. Dietary patterns, cardiovascular risk factors and C-reactive protein in a healthy Italian population. *Nutr Metab Cardiovasc Dis.* 2009;19(10):697-706. [PubMed] [Google Scholar]
 55. Byrne N, Velasco Forte M, Tandon A, Valverde I, Hussain T. A systematic review of image segmentation methodology, used in the additive manufacture of patient-specific 3D printed models of the cardiovascular system. *JRSM Cardiovasc Dis.* 2016;5:2048004016645467. [PubMed] [Google Scholar]
 56. Weisz G, Metzger DC, Caputo RP, Delgado JA, Marshall JJ, Vetrovec GW, Reisman M, Waksman R, Granada JF, Novack V, Moses JW, Carrozza JP. Safety and feasibility of robotic percutaneous coronary intervention: PRECISE (Percutaneous Robotically-

- Enhanced Coronary Intervention) Study. *J Am Coll Cardiol.* 2013;61(15):1596-600. [PubMed] [Google Scholar]
57. Granada JF, Delgado JA, Uribe MP, Fernandez A, Blanco G, Leon MB, Weisz G. First-in-human evaluation of a novel robotic-assisted coronary angioplasty system. *JACC Cardiovasc Interv.* 2011;4(4):460-5. [PubMed] [Google Scholar]
58. Vukicevic M, Mosadegh B, Min JK, Little SH. Cardiac 3D printing and its future directions. *JACC Cardiovasc Imaging.* 2017;10(2):171-84. [PubMed] [Google Scholar]
59. Valverde I. Three-dimensional printed cardiac models: applications in the field of medical education, cardiovascular surgery, structural heart interventions. *Rev Esp Cardiol (Engl Ed).* 2017;70(4):282-91. [PubMed] [Google Scholar]